- Home
- GENK vs IRD Comparison
GENK vs IRD Comparison
Compare GENK & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- IRD
- Stock Information
- Founded
- GENK 2011
- IRD 2018
- Country
- GENK United States
- IRD United States
- Employees
- GENK N/A
- IRD N/A
- Industry
- GENK Restaurants
- IRD
- Sector
- GENK Consumer Discretionary
- IRD
- Exchange
- GENK Nasdaq
- IRD NYSE
- Market Cap
- GENK 20.4M
- IRD 62.0M
- IPO Year
- GENK 2023
- IRD N/A
- Fundamental
- Price
- GENK $4.03
- IRD $1.00
- Analyst Decision
- GENK Strong Buy
- IRD Strong Buy
- Analyst Count
- GENK 2
- IRD 3
- Target Price
- GENK $10.00
- IRD $6.33
- AVG Volume (30 Days)
- GENK 59.5K
- IRD 795.7K
- Earning Date
- GENK 07-30-2025
- IRD 08-15-2025
- Dividend Yield
- GENK 0.78%
- IRD N/A
- EPS Growth
- GENK N/A
- IRD N/A
- EPS
- GENK N/A
- IRD N/A
- Revenue
- GENK $214,957,000.00
- IRD $13,651,000.00
- Revenue This Year
- GENK $16.62
- IRD $51.41
- Revenue Next Year
- GENK $20.40
- IRD $68.84
- P/E Ratio
- GENK N/A
- IRD N/A
- Revenue Growth
- GENK 14.40
- IRD N/A
- 52 Week Low
- GENK $3.16
- IRD $0.65
- 52 Week High
- GENK $10.33
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- GENK 49.22
- IRD N/A
- Support Level
- GENK $3.80
- IRD N/A
- Resistance Level
- GENK $4.07
- IRD N/A
- Average True Range (ATR)
- GENK 0.23
- IRD 0.00
- MACD
- GENK 0.02
- IRD 0.00
- Stochastic Oscillator
- GENK 58.09
- IRD 0.00
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.